Curis Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 114 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 280.00.In the medium term, the stock price is expected to trend up.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Media Coverage